Webinar: Innovative Adjuvants for Advancing Global Health
Innovative Adjuvants for Advancing Global Health
Join SPI Pharma and Inimmune for an exclusive webinar exploring next-generation adjuvant technologies designed to advance vaccine development and improve global access to immunization.
As part of SPI Pharma's ongoing engagement with the global vaccine community and ahead of the upcoming DCVMN Annual General Meeting, this webinar will highlight innovative, globally licensable adjuvant platforms that support the development of safe, effective, and accessible vaccines.
What You'll Learn
During the webinar, SPI Pharma and Inimmune will explore globally licensable and scalable vaccine adjuvant platforms, including QS-21 and TLR4 agonist-based liposomal systems, as well as squalene- and alum-based technologies formulated in combination with a synthetic MPL analogue. The discussion will also highlight INI-2002, an affordable and stable TLR4 agonist that enables the development of next-generation adjuvant systems. Attendees will gain insight into how these technologies can deliver strong immunogenicity, favorable safety profiles, cost-effective solutions, and performance comparable to leading commercial adjuvants.
Featured Speakers
Peter Tygesen
Business Development Director, Vaccine Adjuvants, SPI Pharma
Peter Tygesen brings more than 30 years of pharmaceutical industry experience and has spent over a decade focused on vaccine adjuvant innovation. He has played a significant role in supporting the development and commercialization of adjuvant technologies used globally.
Dr. Juhienah Khalaf
Director of Chemistry, Inimmune Corporation
Dr. Khalaf specializes in the design and development of novel vaccine adjuvants and immunomodulators, with expertise spanning medicinal chemistry, formulation, and CMC development. Her work focuses on technologies that enhance immune responses while expanding access to innovative vaccine solutions.
Who Should Attend?
This webinar is ideal for professionals involved in:
- Vaccine research and development, including antigen and adjuvant selection
- Adjuvant research and technology development
- Preclinical and translational development
- Business development, licensing, and strategic partnerships
- Global health and vaccine accessibility initiatives